



HAL
open science

Identification of defensive antimicrobial compounds from environmental *Serratia marcescens* SNB-CN88 strain associated with macro-holobiont (termite nest) using a molecular network approach

Nguyen Dung, Marceau Levasseur, Juliette Segret, Jonathan Sorres, Téo Hebra, David Touboul, Véronique Eparvier

► To cite this version:

Nguyen Dung, Marceau Levasseur, Juliette Segret, Jonathan Sorres, Téo Hebra, et al.. Identification of defensive antimicrobial compounds from environmental *Serratia marcescens* SNB-CN88 strain associated with macro-holobiont (termite nest) using a molecular network approach. *Comptes Rendus. Chimie*, 2024, 26 (S2), pp.1-13. 10.5802/crchim.259 . hal-04451111


HAL Id: hal-04451111

<https://hal.science/hal-04451111>

Submitted on 11 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



INSTITUT DE FRANCE
Académie des sciences

Comptes Rendus

Chimie


Nguyen Dung, Marceau Levasseur, Juliette Segret, Jonathan Sorres, Téo Hebra,
David Touboul and Véronique Eparvier

Identification of defensive antimicrobial compounds from environmental *Serratia marcescens* SNB-CN88 strain associated with macro-holobiont (termite nest) using a molecular network approach

Volume 1, issue 0 (0000), p. 000-000

<https://doi.org/10.5802/crchim.259>

Part of Special Issue: Chemical Ecology – Chemical Mediation in the Environment

 This article is licensed under the
CREATIVE COMMONS ATTRIBUTION 4.0 INTERNATIONAL LICENSE.
<http://creativecommons.org/licenses/by/4.0/>



Les Comptes Rendus. Chimie sont membres du
Centre Mersenne pour l'édition scientifique ouverte
www.centre-mersenne.org
e-ISSN : 1878-1543



Chemical Ecology – Chemical Mediation in the Environment

Identification of defensive antimicrobial compounds from environmental *Serratia marcescens* SNB-CN88 strain associated with macro-holobiont (termite nest) using a molecular network approach

Nguyen Dung^a, Marceau Levasseur^a, Juliette Segret^a, Jonathan Sorres^a, Téo Hebra^a, David Touboul^{a, b} and Véronique Eparvier^{*, a}

Q1
Q2

^a Université Paris-Saclay, CNRS, Institut de Chimie Des Substances Naturelles, UPR 2301, 91198 Gif-Sur-Yvette, France

^b Laboratoire de Chimie Moléculaire (LCM), CNRS UMR 9168, École Polytechnique, Institut Polytechnique de Paris, 91128 Palaiseau, France

E-mails: dungnvp14@gmail.com (N. Dung), marceau.levasseur@cnrs.fr (M. Levasseur), juliette.segret@cnrs.fr (J. Segret), jon.sorres@gmail.com (J. Sorres), teo.hebra@uochb.cas.cz; (T. Hebra), david.touboul@cnrs.fr (D. Touboul), veronique.eparvier@cnrs.fr (V. Eparvier)

Abstract. Environmental microbes are an underexploited resource for the discovery of bioactive compounds. An integrated approach combining reversed-phase high-performance liquid chromatography and high-resolution tandem mass spectrometry with the use of molecular networks was applied to annotate novel chemical structures with potential antimicrobial activities. This metabolomic approach coupled with biological screening of environmental strains allowed the identification of 22 compounds, including 11 glucosamine derivatives and 10 cyclopeptides, from a bacterial strain of *Serratia marcescens*. Three new glucosamine derivatives and two stephensiolides were annotated. Two antibacterial stephensiolides, named stephensiolides E and F, were isolated to confirm annotations.

Keywords. *Serratia marcescens*, Environmental microorganism, Antimicrobial, Stephensiolide, Glucosamine.

Funding. This work has benefited from an “Investissement d’Avenir” grant managed by the French National Research Agency (CEBA, ref. ANR-10-LABX-0025).

Not yet published

1. Introduction

Plants are the main sources of natural products and have contributed to the discovery of drugs for the

treatment of various human diseases [1,2]. However, the arsenal of specialized metabolites has been recently expanded to include those of microbial origin and, among others, those associated with plants and insects [3–5]. Indeed, the discovery of penicillin isolated from *Penicillium* sp. fungus led to the search

* Corresponding author.

for many other classes of antimicrobial compounds in the fungal and bacterial kingdoms. Actually, the effectiveness of antimicrobial drugs is decreasing while the resistance of microorganisms is significantly increasing [6]. The rapid spread and emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria and fungi are considered to be major threats to global public health in the 21st century [7,8]. Over the last few decades, many of the existing drugs used to treat infectious diseases have become increasingly ineffective because of the global emergence of antimicrobial resistance (AMR). Therefore, there is a constant demand to find new, effective compounds that could help alleviate some of this pressure.

Symbiotic microorganisms have captured the attention of many researchers because they can produce novel bioactive compounds [3–5], many of which possess broad-spectrum antimicrobial activities [9]. However, while highly promising, research in this area is still in its infancy. Symbiotic microbes produce a plethora of bioactive compounds that promote the health of their host and may lead to the ecological success of holobionts (such as plant and/or insect holobionts) [10,11]. Therefore, these environmental microorganisms have the ability to produce antimicrobial compounds because of the constant environmental pressure. The selection pressure is even stronger in areas with high biodiversity [12–14]. Thus, we focused our research efforts in the team Functional Chemistry—Chemical Ecology of *Institut de Chimie des Substances Naturelles* (ICSN of the *Centre National de la Recherche Scientifique* (CNRS)) on our library of symbiotic strains from French Guiana, including those associated with insects or plants, from which many antimicrobial compounds have been isolated recently [15–25]. Among several strain extracts tested in a broad range of antimicrobial assays, the SNB-CN88 crude extract showed a minimal inhibitory concentration (MIC) of 8 $\mu\text{g}/\text{mL}$ against methicillin-resistant *Staphylococcus aureus* (MRSA) without cytotoxicity on healthy human cells (MRC5 lines).

SNB-CN88, isolated from a termite nest, was identified as a strain of *Serratia marcescens*, a bacterial species widely distributed in the environment and an opportunistic Gram-negative nosocomial pathogen belonging to the *Enterobacteriaceae* family. This bacterium isolated from a termite nest had already

been observed in French Guiana, associated with mosquito colonies [26].

In our study, approaches based on high-resolution mass spectrometry (HRMS) and tandem mass spectrometry (MS/MS) were used to explore the specialized metabolome of the mutualistic bacterial strain SNB-CN88. Molecular diversity was annotated in a first step by exploring the molecular network generated by MS/MS data, finely studying fragmentation patterns, and then proposing putative *in silico* structures. In a second step, the isolation of the bioactive compounds was performed to confirm their structures and determine their antibacterial activities.

2. Results and discussion

Molecular network (MN) is now considered a standard bioinformatic tool in the metabolomic community. Its paradigm is based on the observation that compounds with a high degree of structural similarity share comparable MS/MS fragmentation patterns. To provide a clear separation between MS/MS spectral clusters, only the most relevant similarity scores are selected using dedicated filtering steps. In this study, we used MetGem [27,28] to explore the metabolome of *Serratia marcescens*. This software allows the parallel investigation of two complementary representations of a raw dataset, one based on a classic GNPS-style MN and another based on the t-SNE algorithm [27–29]. The t-SNE graph preserves the relationships between related groups of spectra, while the MN output allows an unambiguous separation of clusters. This multivariate embedding method focuses on local distances using nonlinear outputs to represent the entire data space. The relevance of the t-SNE output and its ability to accurately map the spectral distribution of the metabolome of *Serratia marcescens* will be illustrated in the following experiments.

In this study, the crude extract of *Serratia marcescens* SNB-CN88 strain was fractionated into 18 fractions (F2 to F19) and each fraction was tested against MRSA. Fractions F14 and F15 exhibited the highest quantities (F14 (257 mg), F15 (467 mg)) as well as the highest activities (MIC < 32 $\mu\text{g}/\text{mL}$, Supplementary Table S1). The activities observed for the fractions were lower than those of the crude extract, suggesting a synergistic or additive effect of the compounds in the mixture. Therefore, we sought to




Figure 1. t-SNE molecular network generated from metabolic extract fractions of *Serratia marcescens* SNB-CN88 colored according to their MIC against MRSA. Dereplicated clusters are circled in black. Dereplicated specialized metabolite clusters with MICs <64 µg/mL are circled in blue for cluster A, red for cluster B and green for cluster C. Node sizes are relative to the maximum intensity of ions in the whole dataset.

identify most of the metabolites in the SNB-CN88 extract. All fractions were then analyzed by liquid chromatography coupled to tandem high-resolution mass spectrometry (LC-HRMS/MS) in positive ion mode with data-dependent acquisition (DDA) mode. The generated MS/MS data were processed to create a molecular network (MN) using MetGem software and the t-SNE algorithm, which allows visualization of cluster proximity [27,28]. Molecules with intense MS signals are present in clusters A, B, and C in t-SNE MN. These clusters group fractions identified as the most active against MRSA and mainly belong to fractions F14 and F15 (Figure 1).

In order to annotate active molecules, a reduced t-SNE molecular network from only the F14 and F15 fractions was generated from 1221 nodes with m/z values ranging from 211 to 1361. As expected, clusters A, B, and C were also identified in this reduced MN (Figure 2).

A first annotation was performed by interrogating MS/MS spectral databases. To refine the annotation of the features and to respect the standards of reproducible science, the annotation levels proposed by the Metabolomics Standards Initiative (MSI) were used [29]. Level 0 corresponds to an unambiguous 3D structure obtained from isolated pure compounds, level 1 corresponds to the compound identified in comparison with a standard, level 2 corresponds to a putative annotation (MS/MS library comparison or tentative structure), level 3 includes a chemical class assignment (comparison with literature), and level 4 corresponds to unknown molecules (Supplementary Table S2).

The molecules in cluster A were searched using PubChem. The proposed structures described in the literature led to the annotation of already reported natural compounds, i.e., glucosamine derivatives (Figure 3) [30,31]. These compounds are small




Figure 2. t-SNE molecular network generated from active fractions of F14 and F15 of *Serratia marcescens* SNB-CN88. Dereplicated specialized metabolite clusters are circled in blue for cluster A, red for cluster B and green for cluster C. Node sizes are relative to the maximum intensity of ions in the whole dataset.

molecules (m/z 545 to 627 for $[M+H]^+$ ions) composed of a sugar (glucose, hexose), an amino acid (valine), a fatty acid (C13 to C17), and a butyric or oxo-hexanoic acid. The highly intense fragment ion corresponding to the sugar moiety was observed at m/z 232.1177, leading to several fragments at m/z 214.1071 (loss of one water molecule), 196.0981 (loss of two water molecules), 166.0859, 144.0652, and 126.0546 (Supplementary Figures S1–S7). Compound **1** shows a molecular peak at m/z 559.3950 $[M+H]^+$ (calculated 559.3953, err. 0.5 ppm) corresponding to the molecular formula of $C_{29}H_{55}N_2O_8$. This compound has a fatty acid moiety labelled at

m/z 328.2819 (saturated C_{14} fatty acid chain with a valine residue calculated 328.2840, err. 6 ppm) and a glucose residue bound to butyric acid labelled at m/z 232.1181 (calculated 232.1176, err. –2 ppm); therefore, its structure is similar to the glucosamine derivative **1** (Supplementary Figure S1) [30,31].

Similar to compound **1**, each compound in cluster A exhibits a major fragment at m/z 232.1 and their fragments (Supplementary Figures S2–S7). Compounds **2–7** have been annotated by comparison with the literature as glucosamide derivatives analogs (Glu) A, C, D, E, F, H and L. MS/MS spectrum of compounds **8, 9** and **10** showed a fragment at m/z




Figure 3. (A) Annotated Cluster C obtained for t-SNE molecular network generated. (B) Enlargement of nodes for annotation. The color of the nodes is relative to the representation of the fractions F14 (blue) and F15 (red) and their sizes relative to the maximum intensity of these ions in the whole dataset.

Q3

348.2525, 340.2839 and 370.2944, respectively, corresponding to a valine residue bound to a C₁₆ fatty acid with a **four double bond** and a C_{15:1} fatty acid for **8** and **9** (Supplementary Figure S7). MS/MS data from compound **10** show a major fragment which **corresponded** to valine linked to a saturated C₁₇ fatty acid acyl chain and not a C_{16:0H} as described previously for Glucosamine derivatives L [30]. These three new annotated glucosamine derivatives **8–10** were named glucosamine derivatives O, P and L [30–33].

Cluster B contains compounds related to *N*-acetyl-D-glucosamine and was annotated via the GNPS databases (Figure 4). Indeed, the only derepli-

cated compound of cluster B is the potential precursor of the compounds of cluster A. This molecule exhibits a *m/z* value at 232.1177 and corresponds to the calculated chemical formula of C₁₀H₁₈NO₅ (err. 1.1 ppm, Supplementary Figure S8). Compound **11** was dereplicated by MS data as *N*-(2-ethyl-3,4-dihydroxy-3,4-dihydro-2*H*-pyran-5-yl)butyramide.

The different nodes observed in cluster B suggest that different sugars may be present in our extract. Thanks to the use of the t-SNE algorithm, we were able to annotate the glucosamine precursor **11**, observed as a solitary node when using classical GNPS-like representation [30,31].

Q4

Q5




Figure 6. Major NMR correlations observed for compounds **14** and **15**, COSY correlations are shown in bold and HMBC correlations by arrows.

fraction F14 and 5 subfractions from F15 were obtained by flash chromatography (Supplementary Table S1). All these fractions were biologically tested showing that fractions F14.F and F15.E are the most active with MIC at 32 and 8 $\mu\text{g}/\text{mL}$, respectively (Supplementary Table S1).

The purification of fraction F14.F allowed us to isolate the major compound **14**. The HR-ESI-MS analyses show a molecular peak at m/z 654.4108 $[\text{M}+\text{H}]^+$ corresponding to the calculated molecular formula of $\text{C}_{32}\text{H}_{56}\text{N}_5\text{O}_9$ (calculated 654.4078, err. 4.58 ppm). Analysis of the ^1D and ^2D NMR spectra and LC-MS/MS indicated the presence of five amino acids: threonine and two valine and serine residues (Supplementary Figures S18–S24). A large aliphatic peak in the ^1H NMR spectrum of compound **14** suggested the presence of a long alkyl chain typical of lipopeptides. HMBC correlations indicated that the nitrogen atom of the threonine was acylated with this alkyl chain, whereas the shift of Thr H-2 suggested that the hydroxyl group of threonine was esterified (Figure 6). Further HMBC correlations show that threonine is linked to valine via an ester bond and to serine through an amide bond. The positions of the remaining serine and valine residues were determined by COSY correlations between NH and H-1 and HMBC correlations between NH/H-1/H-2 and their respective carbonyls (Figure 6). Purification of the F15.E fraction allowed us to isolate the major compound **15**. HR-ESI-MS analyses show a molecular peak at m/z 668.4224 $[\text{M}+\text{H}]^+$ (calculated 668.4229, err. 0.8 ppm) corresponding to the calculated molecular formula of $\text{C}_{33}\text{H}_{57}\text{N}_5\text{O}_9$. MS and NMR analysis of this compound determined the

presence of the following 5 amino acids: threonine, valine, isoleucine, and two serine residues, as well as the presence of an alkyl chain (Supplementary Figures S25–S30). The amino acid residue chain was determined in the same way as that for compound **14** (Figure 6). The masses of these two compounds allow us to determine that we have C_{12} fatty acid chains. The olefinic signals in the ^1H NMR spectra for **14** and **15** and two carbons in ^{13}C NMR observed at 130.1/128.9 and 131.9/129.6 ppm, respectively, suggest the presence of a double bond within the lipid side chain. The location of these double bonds for **14** and **15** were determined by HMBC correlations to be between the C-5 and C-6 carbons in the acyl chain. The ^{13}C shifts of the vinyl carbons along with constants between the sp^2 proton (10.9 Hz, Supplementary Figure S26) suggest the Z isomer [37–39]. All the experimental ^1D and ^2D NMR data and comparison with the literature allowed us to determine that stephensiolides E (**14**) and F (**15**) were isolated [30–36].

The compounds predominantly found in fractions F14 (**12–14**) and F15 (**14–20**) seem to be responsible for the observed activities. The major compounds **14** and **15** isolated from fractions F14.F and F15.E showed antimicrobial activity against MRSA (MIC = 4 and 8 $\mu\text{g}/\text{mL}$, respectively). Only StpE (**14**) is found in a large proportion in these two fractions. This result can explain the observed antimicrobial activity of the *Serratia marcescens* strain. Compounds **14** and **15** were previously isolated from *Serratia* sp. and *Lecanicillium* sp. strains and showed activity against *Bacillus subtilis* and MRSA (MICs < 32 $\mu\text{g}/\text{mL}$) [34,35]. The metabolites **12–17** named stpC, D, F, G, and I

were also isolated from the *Lecanicillium* sp. strain and showed activity against MRSA with MIC values of 128, 32, 32, 16 and 4 µg/mL, respectively, whereas weak or no activity was observed in a previous study for other stephensiolides (StpQ, StpR, StpK) against *S. aureus*, with MIC higher than 300 µg/mL [31].

3. Conclusion

The molecular network approach using the t-SNE algorithm allowed us to easily annotate new target compounds responsible for the observed biological activity on MRSA. Our study highlighted that *Serratia marcescens* SNB-CN88, isolated from a termite nest, could produce diverse stephensiolides and glucosamine analogs with antimicrobial activity against methicillin-resistant *Staphylococcus aureus* (MRSA). Moreover, 22 compounds were annotated; 2 stephensiolides and 3 glucosamine derivatives were identified for the first time in this study, and two major compounds, including new metabolites from active fractions of SNB-CN88 crude extract, were isolated and structurally characterized. Compounds **14** and **15** were identified as known stephensiolides E and F (for which ¹³C and ¹H NMR are described for the first time, see Supplementary Table S3). All identified compounds contributed to the observed biological activity of the crude extract and its fractions. First, stephensiolide E and F showed antimicrobial activity against MRSA with MIC ≤ 8 µg/mL. Other compounds that were not isolated in this study could also have antimicrobial activities. In particular, the glucosamine derivative E (**2**), which is present in large amounts in the fractions, has never been isolated, characterized, or tested biologically. This compound may possess antibacterial activity similar to that of its analog (glucosamine derivative C).

Preliminary data suggest that this strain SNB-CN88 of *Serratia marcescens* biosynthesizes different compounds from the strain of the same species published by Clements-Decker *et al.* [30,31] and suggested another operational chemical unit (OCU) of *S. marcescens*, as proposed by Barthélemy *et al.* [40]. Clardy's team determined the biosynthetic origin of stephensiolides by sequencing the genome of *Anopheles*-associated *Serratia* sp. and demonstrated that biosynthesis differed according to the media used *in vitro*, which appear to differ from the

natural environment [36]. Consequently, the strain origin may explain the molecular composition differences observed with those previously published in the literature.

Stephensiolides may play a protective role against entomopathogenic bacteria and viruses [30,31,36]. This study suggests that termite mounds (workers, soldiers, tunnel and nest, here called meta-holobiont) can be putatively protected from biotic aggressions of the environment by association with a *Serratia* sp. strain. In return, this association would allow *Serratia* sp. strains in association with the termite meta-holobiont to be easily propagated in the environment because of the termites' way of life (e.g. swarming, feeding, prospecting...).

The Gram-negative bacterium *Serratia marcescens* is also known to be an opportunistic pathogen responsible for a wide range of human diseases, including ocular, uropathogenic, and respiratory infections [41,42]. Studying the termite microbiome could help to understand the transmission of this human infectious disease and improve our understanding of the complex interspecies relationships that contribute to the transmission of vector-borne infectious agents.

4. Materials and methods

4.1. General experimental procedure

NMR spectra were recorded on Bruker 300, 500, 600, and 700 MHz spectrometers (Bruker, Rheinstetten, Germany). The chemical shifts (δ) are reported as ppm based on the solvent signal, and the coupling constants (J) are in hertz. Preparative HPLC was conducted using a Gilson system equipped with a 322 pumping device, a GX-271 fraction collector, a 171 diode array detector, and a prep ELSII. All solvents were HPLC grade, purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France).

4.2. Isolation and identification of termite mutualistic microorganisms

The strain was isolated in 2009 from an environment (termite aerial nest of *Nasutitermes similis*) sampled in Piste de Saint-Elie in French Guiana (ABSCH-CNA-FR-240495-2). The strain SNB-CN88 from the strain library collection at ICSN was identified as *Serratia marcescens*. Taxonomic marker analyses were

externally performed by BACTUP, France. Bacterial isolates were identified on the basis of 16S rDNA sequence analysis. The sequences were aligned with DNA sequences from GenBank, NCBI (<http://www.ncbi.nlm.nih.gov>, accessed on 7 June 2021), using BLASTN 2.2.28. The sequences were deposited in GenBank under the registry number KJ023777.

4.3. Culture and extraction of microorganisms

4.3.1. General cultivation and extraction procedure

SNB-CN88 was cultivated on 330 Petri dishes (14 cm diameter) at 28 °C for 15 days on potato dextrose agar (PDA) medium (Dominique Dutscher SAS, Brumath, France). The culture medium containing the mycelium was cut into small pieces and macerated three times at room temperature with ethyl acetate (EtOAc) on a rotary shaker (70 rpm) for 24 h. The contents were extracted with 10 L of EtOAc using a separatory funnel. Insoluble residues were removed via filtration, and the organic phase was washed three times with an equivalent volume of water (H₂O), dried with anhydrous solid Na₂SO₄, and then evaporated using a rotary evaporator under reduced pressure and a temperature of 30 °C to yield a crude extract (2.7 g).

4.3.2. Fractionation of SNB-CN88

The crude extract (2.7 g) was fractionated using reverse-phase flash chromatography (Grace Reveleris, Grace, Maryland, USA) with a C18 column and UV and DEDL detectors. A 10-min step gradient of H₂O/formic acid (99.9/0.1)-acetonitrile/formic acid (99.9/0.1) (v/v 95/5, 75/25, 50/50, 20/80, 0/100) with a flow rate of 80 mL/min was performed, followed by a second gradient 50% acetonitrile/formic acid (99.9/0.1)-methylene chloride for 15 min and then 100% methylene chloride in 15 min with a flow rate of 80 mL/min was performed to generate 18 fractions, named F2 (38.8 mg), F3 (19.4 mg), F4 (13.9 mg), F5 (26.6 mg), F6 (83.0 mg), F7 (5.6 mg), F8 (96.9 mg), F9 (62.2 mg), F10 (46.7 mg), F11 (34.6 mg), F12 (76.5 mg), F13 (90.7 mg), F14 (257 mg), F15 (467 mg), F16 (165 mg), F17 (76.5 mg), F18 (26.2 mg) and F19 (586 mg).

The F14 fraction was fractionated by flash reverse phase chromatography using a C18 column and UV and ELSD detectors. A 6.5-min step gradient

of solvent A (H₂O/formic acid (99.9/0.1)) and solvent B (acetonitrile) (v/v 75/15, 0/100) followed by a second gradient 50% acetonitrile (B) and 50% dichloromethane (A) for 6.7 min and finished with a third gradient 100% isopropyl alcohol for 10 min with a flow rate of 30 mL/min were performed to generate 7 fractions, named F14.A (2.1 mg), F14.B (0.9 mg), F14.C (1.8 mg), F14.D (3.4 mg), F14.E (17.0 mg), F14.F (42.8 mg), F14.G (0.7 mg).

The F15 fraction was fractionated by flash reverse phase chromatography (CombiFlash NextGen300, Teledyne Technology, USA) using a C18 column and UV and ELSD detectors. A 5.9-min step gradient of solvent A (H₂O/formic acid (99.9/0.1)) and solvent B (acetonitrile) (95:5) followed by a second gradient 57.6% acetonitrile (B) and 42.4% dichloromethane (A) for 8.3 min and a third gradient 54.4% acetonitrile (B) and 45.6% dichloromethane (A) for 2.7 min with a flow rate of 30 mL/min were performed to generate 5 fractions, named F15.A (2.0 mg), F15.B (5.9 mg), F15.C (2.0 mg), F15.D (4.5 mg), F15.E (212.0 mg).

Fractions F14.F and F15.E (20 mg) were re-purified by preparative HPLC (Agilent InfinityLab Proshel 120 × 4 SB-C18, 21.2 × 1500 mm) with the following parameters: flow rate: 21 mL/min, eluents: H₂O + 0.1% formic acid (A) and ACN (B), gradient (using isocratic elution): 40% B to 55% B (in 4 min), 55% B (in 9 min), 55% B to 100% B (in 9 min), 100% B (in 10 min) to give compound **14** (*t_R* 12.8 min, 2.3 mg) and compound **15** (*t_R* 14.8 min, 1.2 mg), respectively.

4.3.3. Molecules isolation and characterization

Stephensiolide E (**14**) white powder; ¹H NMR (700 MHz, DMSO-*d*₆) δ_H Threonine1: 7.94 (1H, d (J = 9.3 Hz), NH), 4.46 (1H, m, H-1), 5.29 (1H, m, H-2), 1.15 (3H, m, H-3), δH Serine2: 7.52 (1H, d (J = 7.6 Hz), NH), 4.25 (1H, m, H-1), 3.47 (1H, m, H-2a), 3.51 (1H, m, H-2b), δH Serine3: 7.84 (1H, d (J = 7.6 Hz), NH), 4.13 (1H, m, H-1), 3.52 (1H, m, H-2a), 3.69 (1H, m, H-2b), Valine4: 7.72 (1H, d (J = 7.3 Hz), NH), 4.13 (H, m, H-1), 2.02 (2H, m, H-2), 0.85 (3H, m, H-4), 0.84 (3H, m, H-3), δH Valine5: 8.39 (1H, d (J = 6.4 Hz), NH), 4.19 (1H, m, H-2), 2.02 (1H, m, H-3), 0.86 (3H, m, H-5), 0.83 (3H, m, H-4), δH Acyl: 5.36 (1H, m, H-5), 5.35 (1H, m, H-6), 2.27 (2H, m, H-2), 2.02 (2H, m, H-4), 1.99 (2H, m, H-7), 1.29 (2H, m, H-8), 1.59 (2H, m, H-3), 1.25 (4H, m, H-9 and H-11), 1.24 (2H, m, H-2, H-10), 0.85 (3H, m, H-12); ¹³C NMR (700 MHz, DMSO-*d*₆) δ_C Threonine1: 168.7 (C, C=O), 55.8

(CH, C-1), 69.9 (CH, C-2), 17.5 (CH₃, C-3); δ C Serine2: 170.5 (C, C=O), 61.3 (CH₂, H-2), 54.6 (CH, C-1), δ C Serine3: 170.6 (C, C=O), 59.7 (CH₂, H-2), 55.2 (CH, C-1), δ C Valine4: 170.7 (C, C=O), 57.8 (CH, C-1), 28.9 (CH, C-2), 19.1 (CH₃, C-3), 18.4 (CH₃, C-4), δ H Valine5: 170.1 (C, C1), 57.5 (CH, C-1), 30.0 (CH, C-2), 18.7 (CH₂, C-3), 18.3 (CH₃, C-4), δ H Acyl: 172.9 (C=O), 130.1 (CH, C-6), 128.9 (CH, C-5), 34.9 (CH₂, C-2), 31.1 (CH₂, C-10), 29.1 (CH₂, C-8), 28.3 (CH₂, C-9), 26.6 (CH₂, C-7), 26.3 (CH₂, C-4), 25.4 (CH₂, C-3), 22.0 (CH₂, C-11), 13.9 (CH₃, C-12). ESI-HRMS m/z [M+H]⁺ 654.4108 (calcd for C₃₁H₅₆N₅O₉H⁺, 642.4078 err. 4.5 ppm).

Stephensiolide F (15) white powder; ¹H NMR (700 MHz, MeOD) δ H Threonine1: 7.07 (1H, d (J = 8.9 Hz), NH), 4.72 (1H, m, H-1), 5.56 (1H, q (J = 6.5 Hz), H-2), 1.29 (3H, m, H-3), δ H Serine2: 7.28 (1H, d, (J = 7.2 Hz), NH), 4.36 (1H, m, H-1), 3.78 (2H, m, H-2), δ H Serine3: 6.96 (1H, d (J = 7.2 Hz), NH), 4.36 (1H, m, H-1), 3.96 (1H, m, H-2a), 3.82 (1H, m, H-2b), δ H Valine4: 7.12 (1H, d (J = 8.9 Hz), NH), 4.24 (1H, t (J = 8.9 Hz), H-1), 2.13 (1H, m, H-2), 0.96 (6H, m, H-3 and H-4), δ H Isoleucine5: 6.96 (1H, d (J = 6.8 Hz), NH), 4.24 (1H, t (J = 6.8 Hz), H-1), 1.82 (1H, m, H-2), 1.51 (1H, m, H-3a), 1.21 (1H, m, H-3b), 0.96 (3H, m, H-4), 0.91 (3H, m, H-5), δ H Acyl: 5.42 (1H, m, H-5), 5.41 (1H, m, H-6), 2.36 (2H, m, H-2), 1.71 (1H, m, H-3), 1.29-1.38 (12H, m, H-4, H7, H8, H9, H10, H11), 0.96 (3H, m, H-12); ¹³C NMR (700 MHz, MeOD) δ C Threonine1: 171.9 (C, C=O), 71.5 (CH, C-2), 57.5 (CH, C-1), 19.7 (CH₃, C-3); δ C Serine2: 173.3 (C, C=O), 62.9 (CH₂, H-2), 56.2 (CH, C-1), δ C Serine3: 173.3 (C, C=O), 56.1 (CH, C-1), 61.0 (CH₂, H-2), δ C Valine4: 170.7 (C, C=O), 57.8 (CH, C-1), 28.9 (CH, C-2), 19.1 (CH₃, C-3), 18.4 (CH₃, C-4), δ H Isoleucine5: 172.5 (C, C=O), 59.8 (CH, C-1), 37.6 (CH, C-2), 27.0 (CH₂, C-3), 15.6 (CH₃, C-4), 14.0 (CH₃, C-5); δ H Acyl: 176.9 (C=O), 131.9 (CH, C-6), 129.6 (CH, C-5), 23.6-36.6 (8CH₂, C-2, C-3, C-4, 7-5, C-8, C-9, C-10, C-11), 11.0 (CH₃, C-12). ESI-HRMS m/z [M+H]⁺ 668.4241 (calcd for C₃₃H₅₆N₅O₉H⁺, 668.4229 err. 0.8 ppm).

4.4. Metabolomic analysis

4.4.1. LC-MS/MS analyses

Crude extract and fractions of SNB-CN88 were prepared at 1 mg/mL in methanol and filtered on a 0.45 μ m PTFE membrane. LC-MS/MS analyses were performed with an HPLC 1260 Prime

chromatography chain (Agilent Technologies, Wald-brom, Germany) coupled with an Agilent 6546 Q-ToF mass spectrometer (Agilent Technologies, Walbronn, Germany). LC separation was performed using an Accucore RP-MS column (100 \times 2.1 mm, 2.6 μ m, Thermo Scientific, Les Ulis, France) with a mobile phase of H₂O/formic acid (99.9:0.1) and acetonitrile/formic acid (99.9:0.1). The column oven was set at 45 °C. The compounds were eluted with a flow rate of 0.4 mL/min with a gradient from 5% B to 100% B in 20 min and then 100% B for 3 min. The injection volume was 5 μ L for all analyses. For the electrospray ionization source, the mass spectra were acquired in positive ionization mode with the following parameters: temperature of the drying gas 325 °C, flow rate of the focalizer gas 10 L/min, capillary voltage 3500 V, nozzle voltage 500 V, fragmentor voltage 130 V, skimmer voltage 45 V and RF voltage of the octopole 1750 V. An internal calibration was performed using two standards: purine and hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazene (m/z 121.0509 and m/z 922.0098), allowing high-resolution masses with less than 5 ppm error. MS/MS data-dependent acquisition was performed on the 5 most intense ions detected by a full MS1 scan in the m/z 200–1000 range, above a threshold of 1000 counts. The selected precursor ions were fragmented with a collision energy set at 30 eV with an isolation window of 1.3 amu. The mass range of the precursor and fragment ions was set between 50 and 1000 m/z .

4.4.2. Data processing analysis

The raw data files were converted from .d format (Agilent Technologies) to .mzML format using MSConvert software, which is part of the Proteo Wizard 3.0 package [43]. All .mzML files were reprocessed using MZmine v. 2.53 software. Mass detection was performed using an MS/MS background noise level of 1000 for MS1 and 50 for MS/MS. The ADAP chromatogram builder was used with a minimum group size of 3, minimum group intensity of 1000, and m/z tolerance of 0.005 (or 15 ppm). Chromatogram deconvolution was performed with the ADAP wavelet algorithm using the following parameters: a threshold signal-to-noise ratio of 30, a minimum component peak height of 50 000, a threshold coefficient/area ratio of 10, a peak duration of 0.001–1 min, and a wavelet retention time range of 0.01–0.08 min. Isotope clustering was performed

using the isotope peak clustering algorithm with an m/z tolerance of 0.005 (or 15 ppm) and a retention time tolerance of 0.1 min. Peaks were filtered using the filter function of the component list to remove all components associated with no MS/MS spectrum. Peak alignment was performed using the attached alignment function, with an m/z tolerance of 0.005 (or 15 ppm), a weight for m/z of 80, a retention time tolerance of 0.1 min, and a weight for retention time of 20. The “export/import” function was used to generate .mgf and .csv files. MetGem version 1.3.4 was used to generate the molecular networks. To add a “network” visualization, the spectra were filtered by keeping the 10 most intense peaks in a sliding window in the spectrum of ± 50 Da. Peaks present in the range of ± 17 Da around the m/z of the precursor ion were removed. The m/z tolerance to match peaks was set at 0.04 Da, and cosine scores were only considered when a minimum of two peaks were matched between 2 spectra. The number of iterations, perplexity, learning speed, and early exaggeration were set to 5000, 25, 10, and 12, respectively, for the t-SNE representation. Figures were generated using the MetGem export function and ChemDraw Professional 16.0 (PerkinElmer). The NMR spectra were processed and analyzed using TopSpin 3.6.2 (Bruker, Rheinstetten, Germany).

4.5. Biological essay

The crude extracts and pure isolated compounds were tested on human pathogenic methicillin-resistant *Staphylococcus aureus* (ATCC 33591). The test was performed in conformance with the reference protocols of the European Committee on Antimicrobial Susceptibility Testing [44]. The MIC was obtained after 24 h. Vancomycin was used as a positive control.

For cytotoxic assays, the crude extracts and isolated compounds were tested in triplicate at concentrations of 10 $\mu\text{g/mL}$ and 1 $\mu\text{g/mL}$ in the MRC5 cell line (ATCC CCL-171, Human Lung Fibroblast Cells), following the procedure described by Tempête *et al.* [45].

Declaration of interests

The authors do not work for, advise, own shares in, or receive funds from any organization that could

benefit from this article, and have declared no affiliations other than their research organizations.

Acknowledgments

The authors are grateful to N. Pollet, Université Paris-Saclay, CNRS, IRD, Évolution Génomes Comportement & Écologie, 91198 Gif-Sur-Yvette, France for their assistance in strain identification.

Supplementary data

Supporting information for this article is available on the journal’s website under <https://doi.org/10.5802/crchim.259> or from the author.

References

- [1] E. K. Davison, M. A. Brimble, *Curr. Opin. Chem. Biol.*, 2019, **52**, 1-8.
- [2] A. L. Harvey, *Curr. Opin. Chem. Biol.*, 2007, **11**, 480-484.
- [3] M. Mudalungu, C. Tanga, S. Kelemu, B. Torto, *Antibiotics*, 2021, **10**, article no. 621.
- [4] C. Beemelmans, H. Guo, M. Rischer, M. Poulsen, *J. Org. Chem.*, 2016, **12**, 314-327.
- [5] D. J. Caruso, E. A. Palombo, S. E. Moulton, B. Zaferanloo, *Microorganisms*, 2022, **10**, article no. 1990.
- [6] N. Waglechner, D. Wright, *B.M.C. Biol.*, 2017, **15**, 1-8.
- [7] A. L. Colombo, J. N. Júnior, J. Guinea, *Curr. Opin. Infect. Dis.*, 2017, **30**, 528-538.
- [8] M. W. McCarthy, D. P. Kontoyiannis, O. A. Cornely, J. R. Perfect, T. J. Walsh, *J. Infect. Dis.*, 2017, **216**, S474-S483.
- [9] N. Adnani, S. R. Rajski, T. S. Bugni, *Nat. Prod. Rep.*, 2017, **34**, 784-814.
- [10] J. C. Simon, J. R. Marchesi, C. Mougél, M. A. Selosse, *Microbiome*, 2019, **7**, article no. 5.
- [11] C. Itis, K. Tougeron, T. Hance, P. Louâpre, V. Foray, *Environ. Microbiol.*, 2022, **24**, 18-29.
- [12] Y. Shennan-Farpón, P. Visconti, K. Norris, *Biotropica*, 2021, **53**, 1276-1289.
- [13] J. X. Becerra, *Proc. Natl. Acad. Sci. USA*, 2015, **112**, 6098-6103.
- [14] T. Hoffman, D. Krug, N. Bozkurt, S. Duddela, R. Jansen, R. Garcia, K. Gerth, H. Steinmetz, R. Müller, *Nat. Commun.*, 2018, **9**, article no. 803.
- [15] S. Sorres, T. Hebra, N. Elie, C. Leman-Loubière, T. Grayfer, P. Grellier, D. Touboul, D. Stien, V. Eparvier, *Molecules*, 2022, **27**, article no. 1182.
- [16] J. Sorres, A. Sabri, O. Brel, D. Stien, V. Eparvier, *Phytochemistry*, 2018, **151**, 69-77.
- [17] J. Sorres, C. Nirma, V. Eparvier, D. Stien, *Org. Lett.*, 2017, **9**, 3978-3981.
- [18] C. Nirma, V. Eparvier, D. Stien, *J. Antibiot.*, 2015, **68**, 586-590.
- [19] C. Nirma, V. Eparvier, D. Stien, *J. Nat. Prod.*, 2015, **78**, 159-162.
- [20] C. Nirma, V. Eparvier, D. Stien, *J. Nat. Prod.*, 2013, **76**, 988-991.
- [21] T. Hebra, N. Elie, S. Poyer, E. Van Eslande, D. Touboul, V. Eparvier, *Metabolite*, 2021, **11**, article no. 444.

- [22] T. Hebra, N. Pollet, D. Touboul, V. Eparvier, *Sci. Rep.*, 2022, **12**, article no. 17310.
- [23] T. M. Casella, V. Eparvier, H. Mandavid, A. Bendelac, G. Odonne, L. Dayan, C. Duplais, L. S. Espindola, D. Stien, *Phytochemistry*, 2013, **96**, 370-377.
- [24] L. A. Peyrat, V. Eparvier, C. Eydoux, J. C. Guillemot, M. Litaudon, D. Stien, *J. Nat. Prod.*, 2020, **83**, 2330-2336.
- [25] M. Barthélemy, E. Elie, L. Pellissier, J. L. Wolfender, D. Stien, D. Touboul, V. Eparvier, *Int. J. Mol. Sci.*, 2019, **20**, 1083.
- [26] K. Heu, O. Romoli, J. C. Schönbeck, R. Ajenoë, Y. Epelboin, V. Kircher, E. Houël, Y. Estevez, M. Gendrin, *Front. Microbiol.*, 2021, **12**, article no. 645701.
- [27] M. Wang, *Nat. Biotechnol.*, 2016, **34**, 828-837.
- [28] F. Olivon, N. Elie, G. Grelier, F. Roussi, M. Litaudon, D. Touboul, *Anal. Chem.*, 2018, **90**, 13900-13908.
- [29] J. Godzien, A. Gil de la Fuente, C. Barbas, *Compr. Anal. Chem.*, 2018, **82**, 415-445.
- [30] T. Clements, M. Rautenbach, T. Ndlovu, S. Khan, W. Khan, *Front. Chem.*, 2021, **9**, article no. 633870.
- [31] T. Clements-Decker, M. Rautenbach, W. van Rensburg, S. Khan, M. Stander, W. Khan, *Sci. Rep.*, 2023, **13**, article no. 2360.
- [32] D. Dwivedi, R. Jansen, G. Molinari, M. Nimtz, B. N. Johri, V. Wray, *J. Nat. Prod.*, 2008, **71**, 637-641.
- [33] A. C. Rustan, C. A. Drevon, *Encyclopedia of Life Sciences*, 2005.
- [34] P.-Y. Mai, M. Levasseur, D. Buisson, D. Touboul, V. Eparvier, *Plants*, 2020, **9**, article no. 47.
- [35] J. G. Ganley, G. Carr, T. R. Iorger, J. C. Sacchettini, E. R. Derbyshire, *Chem. Bio. Chem.*, 2018, **19**, 1590-1594.
- [36] J. G. Ganley, G. Carr, T. R. Iorger, J. C. Sacchettini, J. Clardy, E. R. Derbyshire, *Chem. Bio. Chem.*, 2018, **19**, 1590-1594.
- [37] J. W. de Haan, L. J. M. van de Ven, *Org. Magn. Reson.*, 1973, **5**, 147-153.
- [38] F. D. Gunstone, M. R. Pollard, C. M. Scrimgeour, H. S. Vedanayagam, *Chem. Phys. Lipids*, 1977, **18**, 115-129.
- [39] R. M. Silverstein, F. X. Webster, D. J. Kiemle, *Spectrometric Identification of Organic Compounds*, 7th ed., John Wiley & Sons, New York, 2005, 198 pages.
- [40] M. Barthélemy, V. Guérineau, G. Genta-Jouve, M. Ropy, R. Guillot, L. Pelissier, J. L. Wolfender, D. Stien, V. Eparvier, D. Touboul, *Sci. Rep.*, 2020, **10**, article no. 19788.
- [41] S. D. Mahlen, *Clin. Microbiol. Rev.*, 2011, **24**, 755-791.
- [42] A. Khanna, M. Khanna, A. Aggarwal, *J. Clin. Diagn. Res.*, 2013, **7**, 243-246.
- [43] F. Olivon, G. Grelier, F. Roussi, M. Litaudon, D. Touboul, *Anal. Chem.*, 2017, **89**, 7836-7840.
- [44] European Committee on Antimicrobial Susceptibility Testing: EUCAST, Available online: <https://eucast.org/> (accessed on 11 April 2016).
- [45] C. Tempête, G. Werner, F. Favre, A. Rojas, N. Langlois, *Eur. J. Med. Chem.*, 1995, **30**, 647-650.

AUTHOR QUERIES

- Q1** Please provide ORCID for all authors, if available.
- Q2** Please confirm, author names given ok.
- Q3** Inset labels in Figures 3 and 5 are not clearly visible, please check.
- Q4** Unclear (especially "four"). Please check.
- Q5** "corresponds"?
- Q6** Which strain? Please advise.
- Q7** Multiple references are not allowed under the same key number. So we have splitted most of the references and renumbered the remaining references. Please confirm.
- Q8** Please provide name and place of publisher of ref. [33].
- Q9** Please provide page range/article number of ref. [25].
- Q10** Please provide more details, if possible for ref. [44].